AIMD

Ainos, Inc. (AIMD) Q2 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2025. Ainos, Inc. is an AI and healthcare company focused on scent digitization (AI Nose), point-of-care testing (POCT), and low-dose oral interferon therapeutics (VELDONA). The company operates as a single segment and is classified as a smaller reporting company. All share and per-share data have been retroactively adjusted for a 1-for-5 reverse stock split effective June 30, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased to $4,663 in Q2 2025 from $0 in Q2 2024, driven by sales of VELDONA pet supplements and recognition of $110,379 in revenue from VOC sensing products related to NISD co-development in H1 2025.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 76% in Q2 2025 ($1.84M vs. $1.04M) primarily due to a significant increase in share-based compensation. R&D expenses decreased slightly by 3% ($1.91M vs. $1.98M) due to reduced co-research and staffing costs, partially offset by higher clinical trial fees.
• Debt Structure: The company repaid a $1.0M convertible note (Lee Note) in April 2025. However, total convertible notes payable remain at $11.0M, with $11.0M classified as non-current (related party ASE Note) and $0 current, compared to $3.0M current and $9.0M non-current in the prior year-end.
• Stock Split: A 1-for-5 reverse stock split was executed on June 30, 2025, to maintain Nasdaq listing compliance. Outstanding shares are now 4,267,990.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date. Cash reserves of $1.22M are expected to fund operations for the next 12 months, but additional equity or debt financing will be required. There is no assurance such financing will be available.
• Strategic Focus: The company is prioritizing the commercialization of the AI Nose platform via a "SmellTech-as-a-Service" model in industrial and robotics sectors. Clinical trials for VELDONA (HIV oral warts, Sjögren's syndrome) are ongoing in Taiwan.
• Recent Developments:
  • ASE Order: On August 6, 2025, Ainos secured a $2.1M three-year subscription order with ASE Technology Holding Co., Ltd. to deploy 1,400 AI Nose units.
  • ATM Offering: Between July 1 and August 13, 2025, the company sold 389,871 shares under its At-The-Market facility, raising approximately $1.05M in net proceeds.
  • Nasdaq Compliance: The company regained compliance with Nasdaq's minimum bid price requirement ($1.00) as of July 14, 2025.
• Risks: Key risks include foreign currency exchange fluctuations (operations in Taiwan), dependence on strategic partnerships for revenue, and the need for continued capital raises to fund R&D and operations.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.22M cash balance against the projected burn rate and the timeline for the next financing round.
• Revenue Sustainability: Assess the recurring nature of the $2.1M ASE order and the scalability of the "SmellTech-as-a-Service" model.
• Debt Obligations: Review the terms of the $11M related-party convertible notes (ASE Note), specifically the conversion price mechanics and maturity dates (March 2027).
• Share-Based Compensation: Monitor the impact of high share-based compensation expenses ($1.38M in H1 2025) on future dilution and cash flow.
• Going Concern Status: Confirm if the "substantial doubt" disclosure is resolved by the recent ATM proceeds and the ASE order.